|
Post by JHam on Jan 11, 2021 16:20:14 GMT
Have they said anything about when we can expect the data in january? No, just “January”. On the corporate presentation though it is indicated to be in early January.After looking at the corporate presentation, I guess I should clarify that it is my interpretation that it indicates early January.
|
|
|
Post by magnus123 on Jan 11, 2021 16:26:06 GMT
Thanks. I'm not sure what to do now. More than 100% profit and i'm not sure if i want to take the risk to lose my gains...
|
|
|
Post by JHam on Jan 11, 2021 16:32:53 GMT
Thanks. I'm not sure what to do now. More than 100% profit and i'm not sure if i want to take the risk to lose my gains... You and me both. I continue to adjust stop loss prices just to be safe. I still will keep at least 1/3 of my position. I hate how binary biotechs are. It’s always all or nothing...
|
|
|
Post by selluwud on Jan 11, 2021 16:35:56 GMT
Have they said anything about when we can expect the data in january? No, just “January”. On the corporate presentation though it is indicated to be in early January. Today's run says something good is expected or already known? I'm holding for the end game.
|
|
|
Post by JHam on Jan 11, 2021 16:36:17 GMT
One note though. This is either a run up to data, or someone who knows something. If it’s a run up to data it would be one of the longest run ups to data I’ve ever seen. Several weeks now on above average volume every day. It seems much more like the latter.
|
|
|
Post by magnus123 on Jan 11, 2021 16:48:30 GMT
You are a courageous man, selluwud. I don't know - so I won't do anything right now.
I agree, Jham. I have never seen a run up into data like this. And it's Phase 1 data!
|
|
|
Post by JHam on Jan 11, 2021 17:38:20 GMT
You are a courageous man, selluwud. I don't know - so I won't do anything right now. I agree, Jham. I have never seen a run up into data like this. And it's Phase 1 data! $22.50 as I write this. Decisions decisions...
|
|
|
Post by selluwud on Jan 11, 2021 18:14:06 GMT
I will sell on the data release in expectation of a possible raise. I've been burnt so many times on binary events I eventually have to beat the odds. LOL
|
|
|
Post by JHam on Jan 13, 2021 13:26:48 GMT
Data coming on Jan 21st! us15.campaign-archive.com/?e=7463f8936b&u=4a549c7aea3073da1e942d0ce&id=c69329136bINmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ETWebinar to review expanded biomarker data from the company’s Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer’s disease LA JOLLA, Calif, Jan. 13, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the company will host a Key Opinion Leader (KOL) webinar on Thursday, January 21, from 8:00 AM – 9:00 AM Eastern Time. The webinar will present new biomarker data from the company’s Phase 1b trial of its lead clinical candidate, XPro1595, in patients with Alzheimer’s disease (AD) and biomarkers of inflammation. The primary goal of this 12 week trial is to demonstrate that XPro1595 decreases neuroinflammation. The Company will present expanded biomarker results in patients treated with XPro1595 for at least 12 weeks. “We previously reported that XPro1595 decreased neuroinflammation in AD patients as measured by white matter free water (WMFW), a novel biomarker of inflammation that can be measured non-invasively by MRI,” stated CJ Barnum PhD, Head of Neurosciences at INmune Bio. “Consistent with our approach to study a small number of patients intensively in early phase studies, this updated data set will report on additional measures that support our primary goal of reducing neuroinflammation and address some of the exploratory biomarkers that relate to neurodegenerative disease.” Webinar participants include: RJ Tesi, M.D., co-founder and Chief Executive Officer of INmune Bio. Dr. CJ Barnum, Ph.D., Head of Neuroscience at INmune Bio. Dr. Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC. Dr. Jaeger is a cognitive neuropsychologist and internationally recognized expert in assessing cognitive endpoints. Dr. Malú Gámez Tansey, Ph.D., Director, Center for Translational Research in Neurodegenerative Disease, Medical College of the University of Florida. Dr. Malu Tansey is an internationally recognized expert in neuroinflammation and neurodegenerative disease, including AD. Of note, Malu is an inventor of XPro’s DN-TNF technology and has been studying the drug’s effects on neuroinflammation for over 20 years. RJ Tesi, M.D., co-founder and CEO of INmune Bio, stated: “We look forward to presenting updated data from this important trial with XPro1595. Our goal is to give investors and clinical experts the information they need to understand the role of XPro1595 in treating neuroinflammation in patients with AD.” KOL Discussion Call Information To participate in this event, you must register in advance. Please click on the link below. After registering, you will receive a confirmation email containing information about joining the webinar. To register and access the live webinar click here Date: January 21, 2021 Time: 8:00 AM Eastern Time About XPro1595 XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.
|
|
|
Post by selluwud on Jan 13, 2021 13:38:44 GMT
The way I read it, the statement:
“Consistent with our approach to study a small number of patients intensively in early phase studies, this updated data set will report on additional measures that support our primary goal of reducing neuroinflammation and address some of the exploratory biomarkers that relate to neurodegenerative disease.”
this says the data supports the primary goal, that can't be a bad thing. Maybe I'm reading too much into the wording???
|
|
|
Post by JHam on Jan 13, 2021 13:46:01 GMT
Data coming on Jan 21st! us15.campaign-archive.com/?e=7463f8936b&u=4a549c7aea3073da1e942d0ce&id=c69329136bINmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ETWebinar to review expanded biomarker data from the company’s Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer’s disease LA JOLLA, Calif, Jan. 13, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the company will host a Key Opinion Leader (KOL) webinar on Thursday, January 21, from 8:00 AM – 9:00 AM Eastern Time. The webinar will present new biomarker data from the company’s Phase 1b trial of its lead clinical candidate, XPro1595, in patients with Alzheimer’s disease (AD) and biomarkers of inflammation. The primary goal of this 12 week trial is to demonstrate that XPro1595 decreases neuroinflammation. The Company will present expanded biomarker results in patients treated with XPro1595 for at least 12 weeks. “We previously reported that XPro1595 decreased neuroinflammation in AD patients as measured by white matter free water (WMFW), a novel biomarker of inflammation that can be measured non-invasively by MRI,” stated CJ Barnum PhD, Head of Neurosciences at INmune Bio. “Consistent with our approach to study a small number of patients intensively in early phase studies, this updated data set will report on additional measures that support our primary goal of reducing neuroinflammation and address some of the exploratory biomarkers that relate to neurodegenerative disease.” Webinar participants include: RJ Tesi, M.D., co-founder and Chief Executive Officer of INmune Bio. Dr. CJ Barnum, Ph.D., Head of Neuroscience at INmune Bio. Dr. Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC. Dr. Jaeger is a cognitive neuropsychologist and internationally recognized expert in assessing cognitive endpoints. Dr. Malú Gámez Tansey, Ph.D., Director, Center for Translational Research in Neurodegenerative Disease, Medical College of the University of Florida. Dr. Malu Tansey is an internationally recognized expert in neuroinflammation and neurodegenerative disease, including AD. Of note, Malu is an inventor of XPro’s DN-TNF technology and has been studying the drug’s effects on neuroinflammation for over 20 years. RJ Tesi, M.D., co-founder and CEO of INmune Bio, stated: “We look forward to presenting updated data from this important trial with XPro1595. Our goal is to give investors and clinical experts the information they need to understand the role of XPro1595 in treating neuroinflammation in patients with AD.”KOL Discussion Call Information To participate in this event, you must register in advance. Please click on the link below. After registering, you will receive a confirmation email containing information about joining the webinar. To register and access the live webinar click here Date: January 21, 2021 Time: 8:00 AM Eastern Time About XPro1595 XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. So what do you all think? It's easy to say that there is no way they would make a webinar event out of this and invite KOLs to speak if the data sucked. On the other hand, it could be a situation where the data was good, but not as robust as what they saw initially in the first few patients. Maybe most patients had a clinical response, but patients need to have more doses later on to maintain the effect...? Just thinking out loud. Would love to hear some thoughts here, as I know my mind is going to explode trying to come up with different scenarios over the next week.
|
|
|
Post by jamesjohnson12 on Jan 13, 2021 14:13:45 GMT
How was the data released for the initial subset of patients? Was it a similar webinar? If so, I would be bullish. I wasn't around back in those days. Would be awesome if we could get some some pre-webinar momentum up to $30 and then I would be happy to sell a portion (25% or so) on Wednesday. That way, I would have cashed out about 100% of the original investment with still a significant stake in the event that data is good and well received by the market. And, protected in the event that the market perceives it as lackluster...
|
|
|
Post by JHam on Jan 13, 2021 14:39:40 GMT
How was the data released for the initial subset of patients? Was it a similar webinar? If so, I would be bullish. I wasn't around back in those days. Would be awesome if we could get some some pre-webinar momentum up to $30 and then I would be happy to sell a portion (25% or so) on Wednesday. That way, I would have cashed out about 100% of the original investment with still a significant stake in the event that data is good and well received by the market. And, protected in the event that the market perceives it as lackluster... Good thinking! I dug up the PR from the last time. The language is almost identical: finance.yahoo.com/news/inmune-bio-inc-announce-interim-130010220.htmlINmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020July 9, 2020 Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time LA JOLLA, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that next week it will report interim data from its Phase Ib clinical study of XPro1595 in Alzheimer’s disease. In addition, INmune will host on July 14 a key opinion leader webinar in which the data will be discussed. The webinar will take place prior to AAIC 2020, the world’s largest and most influential international meeting dedicated to advancing dementia science. AAIC 2020 will run virtually July 27-31. XPro1595 is a selective inhibitor of soluble Tumor Necrosis Factor, a key inflammatory cytokine implicated in causing neuroinflammation in patients with Alzheimer’s disease. The Phase Ib multi-center, open-label, multi-dose study is currently enrolling patients with Alzheimer’s disease who express biomarkers of inflammation. The goal of the proof-of-biology trial is to determine if XPro1595 can reduce neuroinflammatory biomarkers following 12 weeks of treatment. Results will inform the design of a proof-of-concept study using XPro1595 to treat patients with Alzheimer’s disease with biomarkers of inflammation. The study is supported by a $1M Part the Cloud Award from the Alzheimer’s Association. The call will start with a brief presentation of the data by RJ Tesi, M.D., CEO of INmune Bio, and CJ Barnum, Ph.D., Director of Neuroscience at INmune Bio, followed by a panel discussion with the following participants: Rosalyn Lai, M.D., a Psychiatrist and Principal Investigator at KaRa MINDS in Sydney, Australia, which is a site enrolling patients in the study. Max Descoteaux, Ph.D., Professor, Computer Science Department, Sherbrooke University, CSO of Imeka and an expert in imaging brain connectivity, from state-of-the-art diffusion MRI acquisition, reconstruction, tractography and processing to visualization. Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC, an internationally recognized cognitive neuropsychologist. Malu Tansey, Ph.D., Professor of Neuroscience and Neurology at the Medical College of the University of Florida, an internationally recognized expert in neuroinflammation and Alzheimer’s disease. KOL Discussion Call Information To participate in this event, you must register in advance. Please click on the link below. After registering, you will receive a confirmation email containing information about joining the webinar. To register and access the live webinar click here Date: July 14, 2020 Time: 8:00 AM Eastern Time
|
|
|
Post by jamesjohnson12 on Jan 13, 2021 15:08:12 GMT
Awesome, thanks! I think that is definitely bullish. If data was poor or lackluster, I would think that they would just issue a PR with the results rather than scheduling a webinar.
I looked back and was reminded that they did do an offering on the heels of the previous webinar. However, it seems like they received pretty good pricing on the offering and that there really wasn't much of a sell off due to the offering (not sustained anyway). So, I'd guess that there is a pretty reasonable chance of an offering following the data release next week. However, I am not as worried about it having much of a negative impact on price assuming that they can secure decent pricing again (which I believe they will be able to do)
Now I am in a conundrum, maybe I don't take much if any off the table prior to the webinar and let it all ride. I am typically a long term holder, but have regrets not selling a portion on the spike in a few recent positions (ATHX in particular)
|
|
|
Post by magnus123 on Jan 13, 2021 16:19:03 GMT
Biotech companies often schedule a conference call prior to data release and the data is mostly bad. But this is a webinar with KOLs. Huge difference here. The data could be positive and still disappoint the market on the other hand. But from the first reading, i view the webinar with KOLs as a positive thing in contrast to the often used conference calls for bad data, where only the CEO or so appears.
The similarities with the last webinar are also very positive. Thanks for highlighting this, Jham.
|
|
|
Post by vzveteran on Jan 13, 2021 23:29:41 GMT
25.50 aftermarket
|
|
|
Post by selluwud on Jan 14, 2021 13:30:41 GMT
|
|
|
Post by JHam on Jan 14, 2021 14:13:43 GMT
Thanks for the heads up. Nice article. Dan (Tradewinds) mentioned in a post that XPro1595 for AD has the be $20-50B dollar drug. If it turns out that it can reduce neuroinflammation WHILE blocking bad TNF, then it is certainly possible. I’m trying to temper my expectations here, but I can’t lie, I think the data is going to be great. I think that’s why they are having a webinar with KOLs, and why they put in a poison pill.
|
|
|
Post by selluwud on Jan 14, 2021 14:27:28 GMT
Thanks for the heads up. Nice article. Dan (Tradewinds) mentioned in a post that XPro1595 for AD has the be $20-50B dollar drug. If it turns out that it can reduce neuroinflammation WHILE blocking bad TNF, then it is certainly possible. I’m trying to temper my expectations here, but I can’t lie, I think the data is going to be great. I think that’s why they are having a webinar with KOLs, and why they put in a poison pill. This company will get scooped up by a big pharma if this methodology/approach to lessening/stopping/reversing?? Alzheimers is proven out. I'm keeping a stop in place to protect the profit I've gained so far in the event of headwinds.
|
|
|
Post by JHam on Jan 14, 2021 17:29:27 GMT
I wouldn’t be surprised if we see a bit of a retraction here over the next few days now that we know which day they’ll release data. Then a big push again next Tuesday/Wednesday.
|
|